Fortune Smiles 88
讚並評論了
$Esperion Therapeutics (ESPR.US)$Esperion initiated with an Overweight at Cantor Fitzgerald - TipRanks.com BELOW is a Detailed research report that should convince readers to have a portion of their investment portfolio in Esperion. This is not a pump article, please take the time to read and fact check. This $2 stock will be $20+ by 2027. Esperion anticipates billions in Revenues.
Es...
Es...
已翻譯
15
1
Fortune Smiles 88 : 我同意。低風險高收益的機會。每個月凱文多/內瑟立澤的零售價格爲每位患者400美元。僅美國就有100万患者,這將使愛斯貝利的毛收入達到每月40000万美元,或者接近每年近50億美元。將其推廣到全球人口。潛力巨大。